FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping

Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A 46-...

Full description

Saved in:
Bibliographic Details
Published in:Medical principles and practice 2014-01, Vol.23 (5), p.478-481
Main Authors: Yeh, Yung-Sung, Huang, Meng-Lin, Chang, Se-Fen, Chen, Chin-Fan, Hu, Huang-Ming, Wang, Jaw-Yuan
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma - secondary
Angiogenesis Inhibitors - administration & dosage
Antibodies, Monoclonal, Humanized - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
Camptothecin - analogs & derivatives
Camptothecin - therapeutic use
Case Report
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - pathology
Fluorouracil - therapeutic use
Genotype
Glucuronosyltransferase - genetics
Humans
Hyperbilirubinemia - complications
Hyperbilirubinemia - genetics
Leucovorin - therapeutic use
Liver Neoplasms - drug therapy
Liver Neoplasms - genetics
Liver Neoplasms - secondary
Male
Middle Aged
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A 46-year-old male was diagnosed with rectosigmoid colon cancer with liver metastases and hyperbilirubinemia presenting with severe jaundice. UGT1A1 genotyping was used before therapy to ascertain whether genotype-adjusted dosages of irinotecan plus bevacizumab could alleviate the toxicity. Then, the patient was treated with FOLFIRI. Conclusion: The FOLFIRI regimen was successfully used in this patient without concerns regarding toxicity.
ISSN:1011-7571
1423-0151
DOI:10.1159/000358799